Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc's successful validation of its oral small molecule platform and GPCR targeting capabilities, particularly through the positive Phase 2 data for aleniglipron, has bolstered confidence in the company's potential to advance its next-generation assets. The combination of effective titration strategies that enhance the therapeutic index and strong interest in amylin licensing indicates potential material upside as the company progresses through vital clinical trials, with key results expected in 2026. Additionally, with recent equity financing leading to an upward adjustment of the price target, the overall outlook reflects a robust strategy aimed at solving market supply chain issues associated with existing treatments, presenting a strategic advantage for future launches.

Bears say

The financial outlook for Structure Therapeutics is negatively impacted by challenges associated with the bioavailability of oral formulations, particularly the limitations of their leading product, aleniglipron, in comparison to traditional injectables. Concerns surrounding tolerability, exemplified by high rates of nausea and vomiting, hinder the potential for broad adoption in primary care settings, where patients may not tolerate side effects as readily. Additionally, increasing competition in the oral incretin market and risks related to partner engagements further exacerbate uncertainties regarding the commercial viability and market penetration of their therapeutics.

GPCR has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Buy based on their latest research and market trends.

According to 11 analysts, GPCR has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.